Biochemical recurrence after treatment of prostate cancer occurs in 30-50 % of patients. Confirming that recurrence is localized to the pelvis is challenging as PSA is nonspecific and imaging modalities are imperfect in identifying location of recurrent disease. Salvage therapy after radical prostatectomy is limited to external beam radiotherapy and androgen-deprivation therapy. After radiotherapy, local salvage therapy consists of salvage radical prostatectomy, salvage brachytherapy, and salvage high-intensity ultrasound. Each treatment modality provides various rates of cure but with its own side-effect profile, prompting discussion between patient and clinician to determine appropriate treatment course. Local salvage therapy has the potential to be curative and disease control has been reported in a substantial number of select patients. However, the survival benefit of these therapies has yet to be definitively proved.
Furthermore, a short PSA doubling time (PDT) is associated with an increased likelihood of PCSM, irrespective of Gleason score, 6 likely due to the PDT more accurately reflecting the true tumor biology. A PDT of 11.7 months predicts local failure with a low potential for systemic progression and PDT of <4.3 months is associated with a high probability of developing systemic recurrence or existing systemic recurrence. 7 Advanced pathologic features after prostatectomy, such as seminal vesicle invasion, lymph node invasion, poorly differentiated cancer, and positive surgical margins (PSMs) 6 also increase the risk for PCSM.
Interpreting PSA after EBRT is challenging. In 10-30 % of patients, PSA levels will increase-'PSA bounce'-even up to 2 to 3 years after treatment. Although likely due to benign prostate cells left behind, the rise may initially be indistinguishable from a true recurrence. 8 Prostate biopsy
is not recommended by the American Society for Therapeutic Radiology and Oncology (ASTRO) as a positive result has minimal impact on outcome up to 2 years after radiation; 9 however, in a review by Pollack, there was a 50 % progression of PSA at 7 years after EBRT in patients with a positive biopsy. 10 Intervention at the earliest stage after recurrence provides the best chance for cure, and as such any patient with BCR and a positive biopsy 2 or more years after treatment, should undergo salvage therapy especially if no treatment effect is seen on pathology. 11 Once recurrent disease is present the critical matter remains to determine location, local or systemic. Imaging is unreliable to determine location of recurrent disease. Trans-rectal ultrasound and biopsy is difficult to interpret due to sampling errors and unknown time required for cancer cells to become nonviable after radiation. The sensitivity and specificity of trans-rectal ultrasound was not superior to digital rectal exam in predicating a positive biopsy. 12 Useful in pretreatment prostate, magnetic resonance imaging may also helpful in a radiated prostate. Experienced radiologists can distinguish benign prostate tissue from suspicious nodules, to help in biopsy planning and step-section postradiation prostatectomy. 13 After initial treatment, evidence of BCR prompts discussions between the patient and clinician. Systemic therapy, such as androgendeprivation therapy (ADT), can provide long-term disease control for both local and systemic disease. However, there remains debate about whether conventional ADT offers cure for patients with relapsed disease.
Likewise, concerns about long-term toxicity limit its appeal. Further retrospective studies have shown a benefit similar to adjuvant radiotherapy in patients with several risk factors for developing distant metastases and PCSM. In 501 patients who underwent salvage radiotherapy, 38 % with PDT <10 months were disease free at 4 years as were 70 % of men with BCR within 12 months of prostatectomy. Followup studies showed that in high-risk patients who received salvage radiotherapy when PSA levels were 0.5 ng/mL, 41 % were disease free at 6 years, whereas this group of patients have a 60-70 % chance of developing metastases at 6 years if untreated. 5 In practice now, patients with long life expectancy with BCR postprostatectomy are advised salvage radiotherapy based on 2-3 rising PSA levels and radiotherapy started at PSA levels 0.1-0.2 ng/mL, recognizing the risk that the increasing PSA level may be residual benign prostatic glands.
Of the significant risk factors (Gleason score, PDT <10 months and short interval to developing BCR), patients with a short PDT seem to benefit the most from salvage radiotherapy. In a study of 635 patients with BCR after prostatectomy, 238 had salvage radiotherapy and 397 received ADT.
The patients who had salvage radiotherapy had a statistically significantly improved PCSM compared with ADT alone. Subgroup analysis showed that benefit was greatest for patients who had a PDT of <6 months. 16 Complications after salvage radiation are not common but can have significant morbidity. In the SWOG 8794 trial, which albeit studied adjuvant radiotherapy, not salvage radiotherapy, there were significantly more complications in the adjuvant radiotherapy group (23.8 % versus 11.9 %) and certain complications (proctitis and rectal bleeding) were unique to the radiotherapy group. Urethral stricture and total urinary incontinence rates were significantly higher in the radiotherapy group.
Overall assessment of quality of life was similar at 2 years and superior at 3 years in the radiotherapy group. 17 Although radiation of any kind has the potential for causing a secondary malignancy, this may be reduced with improved image-guided techniques, utilizing operative and pathologic reports and guidelines to optimize target volume and margins. 18 Salvage radiotherapy is delivered either to the whole pelvis or to the prostatic fossa. When delivered to the pelvis, the pelvic lymph nodes are 21 In SWOG 8794, it was suggested that lack of local control may diminish response and effectiveness of ADT.
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Salvage Therapy after Radiotherapy Salvage Radical Prostatectomy
Salvage radical prostatectomy represents a local salvage therapy for presumed isolated local recurrence of prostate cancer with curative potential. Only salvage prostatectomy has been shown to provide cancer control for 10 years or more in a substantial proportion of patients.
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The 10-year PSA progression-free probability after salvage prostatectomy alone is 30 % to 43 % and 10-year cancer-specific survival rates of 70 % and 77 % have been reported. 23, 24 Rates are dependent on pathologic findings postsalvage prostatectomy. The 5-year PSA progression-free probability is 77 %, 71 %, and 24 % for patients with organ-confined disease, isolated extra-capsular extension, and seminal vesicle invasion and/or regional lymph node metastases, respectively. 11 However, salvage prostatectomy complications after are higher. In a review of 100 patients undergoing salvage prostatectomy after either EBRT and interstitial radiotherapy, 25 the rate of rectal injury was 13 %, reoperation was 3 %, and one patient required cystectomy due to a urinary fistula. Complication rates are noted to be higher after retropubic radiotherapy compared with EBRT.
Anatomic stricture rate was 30 % with a somewhat higher rate seen in patients receiving EBRT. In terms of urinary incontinence, 68 % of patients required one pad per day and 38 % were completely dry. Compared with primary radical prostatectomy, these rates are significantly higher but are decreasing. 25, 26 Based on a review by Pisters et al., 27 salvage radical prostatectomy, compared with cryosurgery, offers higher biochemicalfree rates with 61 % of patients having PSA <0.4 ng/mL at five years, compared with 21 % in the cryosurgery group. OS was improved: 95 % versus 85 %. Because of the morbidity and complication rate of salvage prostatectomy, but the greatest chance of cure, the ideal candidate should be highly motivated, have a life expectancy >10 years, lack severe medical comorbidities, and have a pre-treatment PSA of <10 ng/mL.
Cryosurgery
When initially used as salvage therapy after radiation, cryosurgery using liquid nitrogen probes, there was significant hesitation due to high rates of incontinence and fistulas. now with use of gas probes with smaller diameters, urethral warming devices, and thermocouplers to prevent freezing of the sphincter, these rates are decreasing and cryosurgery is more accepted as an option for recurrent prostate disease. In the Cryo
On-Line Data (COLD) patients, 279 underwent salvage cryosurgery after radiation for BCR. 28 After a median follow up of 21 months, 58 % remained Complication rate is higher after salvage cryosurgery compared with primary cryosurgery, with erectile dysfunction and pelvic pain being the most common. In the MD Anderson series, 28 % were completely dry postoperatively and moderate to severe voiding symptoms were seen in 66 % of patients; this improved to 8-20 % with the use of modern probes and a urethral warming device. 32 Rectal fistula rate was 1.2 % but reported as high as 11 % in some series; 33 however, decreased rates were seen with the use of urethral warming devices and intraoperative use of ultrasound. Other series reported similar rates, majority within 1 year after cryosurgery. 31, 34 Based on the series and lack of long-term survival data, it appears that salvage cryosurgery is inferior to salvage prostatectomy in terms of cancer control but a more favorable morbidity profile.
Salvage Brachytherapy
The benefit of brachytherapy used in the salvage setting is not as well established. 35, 36 The largest consists of 49 patients 36 with BCR defined as a PSA rise over two measurements. The 3-year BCR-free rate was at the apex and 65 % had foci <5 mm from the urethra, 7 % had urethral involvement. These areas, the apex, periurethral, and urethra, are difficult and problematic areas to treat with both brachytherapy and cryosurgery.
Because of this, in the salvage setting, these therapies may not provide the greatest chance for cure.
Salvage High-intensity Ultrasound
Salvage high-intensity ultrasound (HIFU), similar to cryosurgery, is still somewhat experimental, even in the primary treatment setting. Because of rapid dissipation of energy, treatment is more targeted. In the reported series, disease-free rates ranges from 25-54 %. 40 Murat et al. reviewed
167 patients with BCR defined by ASTRO guidelines with positive biopsies after EBRT who underwent salvage HIFU. 41 After mean follow-up time of 18 months, 41 had positive biopsies prompted by rising PSA and 52 had evidence of BCR but a negative biopsy; 17 patients developed metastatic disease, 11 of whom died. Five-year OS was 84 % with a progression-free survival (PFS) rate of 25 % in the high-risk patient group. Series report urethral stricture or bladder neck contracture rate of 10-20 % and rectourethral fistula late of 3 to 12.5 %. 40 Similar to cryosurgery, salvage HIFU provides only minimal improvement in PFS with significant morbidity and, as such, is not recommended as salvage therapy.
Systemic Therapy
To date, there is no role for systemic chemotherapy in the salvage setting As the majority of men receiving ADT will die of something other than prostate cancer, long-term effects are essential to prevent and treat as needed. ADT is associated with increased obesity and specifically the lack of androgens result in a fall in lean body mass and accumulation of subcutaneous abdominal fat, both of which has been shown to increase mortality. Despite exercise, body composition does not change. Bicalutimide was evaluated as an adjuvant therapy in men with T1b-T4 without lymph node involvement or distant metastases. 45 PFS was improved in all patients, but the greatest improvement was seen in patients with locally advanced disease, regardless of initial therapy modality.
OS was unchanged. 
